{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:22:05Z","timestamp":1793330525698,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41591-024-03478-6","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T10:05:07Z","timestamp":1737367507000},"page":"1134-1144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5115-1321","authenticated-orcid":false,"given":"Julie K.","family":"Jadlowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-7595","authenticated-orcid":false,"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1057-576X","authenticated-orcid":false,"given":"James L.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"McConville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Rogal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1127-8651","authenticated-orcid":false,"given":"Cory","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-2167","authenticated-orcid":false,"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-6992","authenticated-orcid":false,"given":"Yimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0583-8446","authenticated-orcid":false,"given":"Rachel M.","family":"Leskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Farrelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Karar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Barber-Rotenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Gaymon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-537X","authenticated-orcid":false,"given":"Jan Joseph","family":"Melenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja A.","family":"Zolnoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantan","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0600-0709","authenticated-orcid":false,"given":"Angelina","family":"Petrichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9073-6194","authenticated-orcid":false,"given":"Emma J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3724-6373","authenticated-orcid":false,"given":"Carole","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kulikovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Ram\u00edrez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8053-690X","authenticated-orcid":false,"given":"Janna C.","family":"Minehart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar I.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-8465","authenticated-orcid":false,"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-2251","authenticated-orcid":false,"given":"Donald L.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Lledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5943","authenticated-orcid":false,"given":"Gabriela","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-750X","authenticated-orcid":false,"given":"Friederike","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Tebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"DiNofia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-7968","authenticated-orcid":false,"given":"Naomi B.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-7314","authenticated-orcid":false,"given":"Donald M.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janos L.","family":"Tanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-4056","authenticated-orcid":false,"given":"Frederic D.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8993","authenticated-orcid":false,"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"3478_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High, K. A. & Roncarolo, M. G. Gene therapy. N. Engl. J. Med. 381, 455\u2013464 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR3","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","volume":"31","author":"D Chancellor","year":"2023","unstructured":"Chancellor, D., Barrett, D., Nguyen-Jatkoe, L., Millington, S. & Eckhardt, F. The state of cell and gene therapy in 2023. Mol. Ther. 31, 3376\u20133388 (2023).","journal-title":"Mol. Ther."},{"key":"3478_CR4","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132\u20133142 (2008).","journal-title":"J. Clin. Invest."},{"key":"3478_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","volume":"348","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255\u2013256 (2003).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415\u2013419 (2003).","journal-title":"Science"},{"key":"3478_CR7","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"SJ Howe","year":"2008","unstructured":"Howe, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143\u20133150 (2008).","journal-title":"J. Clin. Invest."},{"key":"3478_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nm.2088","volume":"16","author":"S Stein","year":"2010","unstructured":"Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198\u2013204 (2010).","journal-title":"Nat. Med."},{"key":"3478_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2018.08.006","volume":"10","author":"K Cornetta","year":"2018","unstructured":"Cornetta, K. et al. Screening clinical cell products for replication competent retrovirus: the National Gene Vector Biorepository experience. Mol. Ther. Methods Clin. Dev. 10, 371\u2013378 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3478_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","volume":"26","author":"K Cornetta","year":"2018","unstructured":"Cornetta, K. et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. Mol. Ther. 26, 280\u2013288 (2018).","journal-title":"Mol. Ther."},{"key":"3478_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","volume":"26","author":"KT Marcucci","year":"2018","unstructured":"Marcucci, K. T. et al. Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients. Mol. Ther. 26, 269\u2013279 (2018).","journal-title":"Mol. Ther."},{"key":"3478_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley, J. L., de Jong, Y. P., Terhorst, C. & Herzog, R. W. Immune responses to viral gene therapy vectors. Mol. Ther. 28, 709\u2013722 (2020).","journal-title":"Mol. Ther."},{"key":"3478_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","volume":"110","author":"AR Schroder","year":"2002","unstructured":"Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521\u2013529 (2002).","journal-title":"Cell"},{"key":"3478_CR14","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/blood-2007-01-068759","volume":"110","author":"C Cattoglio","year":"2007","unstructured":"Cattoglio, C. et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110, 1770\u20131778 (2007).","journal-title":"Blood"},{"key":"3478_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/mt.2009.16","volume":"17","author":"GP Wang","year":"2009","unstructured":"Wang, G. P. et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol. Ther. 17, 844\u2013850 (2009).","journal-title":"Mol. Ther."},{"key":"3478_CR16","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.V79.7.1768.1768","volume":"79","author":"BG Herndier","year":"1992","unstructured":"Herndier, B. G. et al. Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus type 1-associated T-cell transformation. Blood 79, 1768\u20131774 (1992).","journal-title":"Blood"},{"key":"3478_CR17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.micinf.2007.09.008","volume":"9","author":"H Katano","year":"2007","unstructured":"Katano, H. et al. Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient. Microbes Infect. 9, 1581\u20131589 (2007).","journal-title":"Microbes Infect."},{"key":"3478_CR18","first-page":"2069","volume":"54","author":"B Shiramizu","year":"1994","unstructured":"Shiramizu, B., Herndier, B. G. & McGrath, M. S. Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas. Cancer Res. 54, 2069\u20132072 (1994).","journal-title":"Cancer Res."},{"key":"3478_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8795","volume":"7","author":"JW Mellors","year":"2021","unstructured":"Mellors, J. W. et al. Insertional activation of STAT3 and LCK by HIV-1 proviruses in T cell lymphomas. Sci. Adv. 7, eabi8795 (2021).","journal-title":"Sci. Adv."},{"key":"3478_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"3478_CR21","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 3, 2317\u20132322 (2019).","journal-title":"Blood Adv."},{"key":"3478_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584\u2013586 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"3478_CR24","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805\u20133815 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3478_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong, E. A., Ruella, M., Schuster, S. J. & Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 384, 673\u2013674 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao, W. H. et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 15, 86 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"3478_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro, A. et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol. Blood Marrow Transpl. 26, 26\u201333 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"3478_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2022015728","volume":"140","author":"DHM Steffin","year":"2022","unstructured":"Steffin, D. H. M. et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood 140, 16\u201324 (2022).","journal-title":"Blood"},{"key":"3478_CR29","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR30","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1016\/S2352-3026(23)00212-0","volume":"10","author":"T Trab","year":"2023","unstructured":"Trab, T. et al. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol. 10, e838\u2013e848 (2023).","journal-title":"Lancet Haematol."},{"key":"3478_CR31","doi-asserted-by":"publisher","first-page":"e790","DOI":"10.1016\/S2352-3026(23)00248-X","volume":"10","author":"A Sureda","year":"2023","unstructured":"Sureda, A. & Domingo-Domenech, E. Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation. Lancet Haematol. 10, e790\u2013e791 (2023).","journal-title":"Lancet Haematol."},{"key":"3478_CR32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/blood-2023-182817","volume":"142","author":"P Li","year":"2023","unstructured":"Li, P. et al. C-CAR039, a novel anti-CD20\/CD19 bi-specific CAR T-cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r\/r) B-cell non-Hodgkin lymphoma (B-NHL) in long term follow up. Blood 142, 1025 (2023).","journal-title":"Blood"},{"key":"3478_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"3478_CR34","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli, M. et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N. Engl. J. Med. 390, 2074\u20132082 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR35","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 142, 6939 (2023).","journal-title":"Blood"},{"key":"3478_CR36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"key":"3478_CR37","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"3478_CR38","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","volume":"6","author":"S Gill","year":"2022","unstructured":"Gill, S. et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 6, 5774\u20135785 (2022).","journal-title":"Blood Adv."},{"key":"3478_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.omtm.2016.11.002","volume":"4","author":"E Sherman","year":"2017","unstructured":"Sherman, E. et al. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol. Ther. Methods Clin. Dev. 4, 39\u201349 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3478_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtm.2016.11.003","volume":"4","author":"CC Berry","year":"2017","unstructured":"Berry, C. C. et al. INSPIIRED: quantification and visualization tools for analyzing integration site distributions. Mol. Ther. Methods Clin. Dev. 4, 17\u201326 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3478_CR41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"3478_CR42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey, N. V. et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J. Clin. Oncol. 38, 415\u2013422 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3478_CR43","doi-asserted-by":"publisher","first-page":"971045","DOI":"10.3389\/fimmu.2022.971045","volume":"13","author":"Y Kaminskiy","year":"2022","unstructured":"Kaminskiy, Y., Kuznetsova, V., Kudriaeva, A., Zmievskaya, E. & Bulatov, E. Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion. Front. Immunol. 13, 971045 (2022).","journal-title":"Front. Immunol."},{"key":"3478_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41590-023-01685-w","volume":"25","author":"Z Zhu","year":"2024","unstructured":"Zhu, Z. et al. FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells. Nat. Immunol. 25, 117\u2013128 (2024).","journal-title":"Nat. Immunol."},{"key":"3478_CR45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41586-023-06835-6","volume":"625","author":"R Schmidt","year":"2024","unstructured":"Schmidt, R. et al. Base-editing mutagenesis maps alleles to tune human T cell functions. Nature 625, 805\u2013812 (2024).","journal-title":"Nature"},{"key":"3478_CR46","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.21037\/atm-20-922","volume":"8","author":"Y He","year":"2020","unstructured":"He, Y. & Wang, X. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis. Ann. Transl. Med. 8, 1050 (2020).","journal-title":"Ann. Transl. Med."},{"key":"3478_CR47","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1002\/jcp.30396","volume":"236","author":"R Tashiro","year":"2021","unstructured":"Tashiro, R. et al. Dysregulation of Rnf 213 gene contributes to T cell response via antigen uptake, processing, and presentation. J. Cell Physiol. 236, 7554\u20137564 (2021).","journal-title":"J. Cell Physiol."},{"key":"3478_CR48","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/73536","volume":"24","author":"SA Gayther","year":"2000","unstructured":"Gayther, S. A. et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24, 300\u2013303 (2000).","journal-title":"Nat. Genet."},{"key":"3478_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.14715\/cmb\/2023.69.12.37","volume":"69","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. MiR-26a-5p exerts its influence by targeting EP300, a molecule known for its role in activating the PI3K\/AKT\/mTOR signaling pathway in CD8+ tumor-infiltrating lymphocytes of colorectal cancer. Cell Mol. Biol. (Noisy-le-grand) 69, 232\u2013241 (2023).","journal-title":"Cell Mol. Biol. (Noisy-le-grand)"},{"key":"3478_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc3179","volume":"12","author":"M Sadelain","year":"2011","unstructured":"Sadelain, M., Papapetrou, E. P. & Bushman, F. D. Safe harbours for the integration of new DNA in the human genome. Nat. Rev. Cancer 12, 51\u201358 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"3478_CR51","doi-asserted-by":"crossref","unstructured":"Dup\u00e9r\u00e9-Richer, D. et al. KDM6A regulates immune response genes in multiple myeloma. Blood 144, 1508\u20131520 (2024).","DOI":"10.1182\/blood.2024024518"},{"key":"3478_CR52","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/2159-8290.CD-22-0869","volume":"13","author":"J Lee","year":"2023","unstructured":"Lee, J. et al. Sex-biased T-cell exhaustion drives differential immune responses in glioblastoma. Cancer Discov. 13, 2090\u20132105 (2023).","journal-title":"Cancer Discov."},{"key":"3478_CR53","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkq929","volume":"39","author":"SA Forbes","year":"2011","unstructured":"Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945\u2013D950 (2011).","journal-title":"Nucleic Acids Res."},{"key":"3478_CR54","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/iub.2686","volume":"75","author":"B Deka","year":"2023","unstructured":"Deka, B. et al. RNPS1 functions as an oncogenic splicing factor in cervical cancer cells. IUBMB Life 75, 514\u2013529 (2023).","journal-title":"IUBMB Life"},{"key":"3478_CR55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1101\/gad.1163204","volume":"18","author":"A Nott","year":"2004","unstructured":"Nott, A., Le Hir, H. & Moore, M. J. Splicing enhances translation in mammalian cells: an additional function of the exon junction complex. Genes Dev. 18, 210\u2013222 (2004).","journal-title":"Genes Dev."},{"key":"3478_CR56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fimmu.2013.00206","volume":"4","author":"Y Li","year":"2013","unstructured":"Li, Y., Yin, Y. & Mariuzza, R. A. Structural and biophysical insights into the role of CD4 and CD8 in T cell activation. Front. Immunol. 4, 206 (2013).","journal-title":"Front. Immunol."},{"key":"3478_CR57","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(23)02747-2","volume":"402","author":"R Nelson","year":"2023","unstructured":"Nelson, R. FDA investigating safety risks in CAR T-cell recipients. Lancet 402, 2181 (2023).","journal-title":"Lancet"},{"key":"3478_CR58","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial CAR T cell therapy: analysis of FDA Adverse Events Reporting System (FAERS). Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"3478_CR59","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1182\/blood.V98.6.1979","volume":"98","author":"M Hisada","year":"2001","unstructured":"Hisada, M., Biggar, R. J., Greene, M. H., Fraumeni, J. F. Jr. & Travis, L. B. Solid tumors after chronic lymphocytic leukemia. Blood 98, 1979\u20131981 (2001).","journal-title":"Blood"},{"key":"3478_CR60","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR61","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn, K. & Perales, M. A. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transpl. 57, 1477\u20131488 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"3478_CR62","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.18909","volume":"203","author":"M Mohan","year":"2023","unstructured":"Mohan, M. et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br. J. Haematol. 203, 736\u2013746 (2023).","journal-title":"Br. J. Haematol."},{"key":"3478_CR63","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati, S. et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 6, 2045\u20132054 (2022).","journal-title":"Blood Adv."},{"key":"3478_CR64","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR65","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR66","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386, 629\u2013639 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR67","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"3478_CR68","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR69","doi-asserted-by":"crossref","unstructured":"Morton, L. M., Onel, K., Curtis, R. E., Hungate, E. A. & Armstrong, G. T. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am. Soc. Clin. Oncol. Educ. Book 2014, e57\u2013e67 (2014).","DOI":"10.14694\/EdBook_AM.2014.34.e57"},{"key":"3478_CR70","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamaoncol.2018.4934","volume":"5","author":"A Tichelli","year":"2019","unstructured":"Tichelli, A. et al. Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients. JAMA Oncol. 5, 229\u2013235 (2019).","journal-title":"JAMA Oncol."},{"key":"3478_CR71","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41409-018-0290-6","volume":"54","author":"E Martelin","year":"2019","unstructured":"Martelin, E. et al. Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up. Bone Marrow Transpl. 54, 334\u2013337 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"3478_CR72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI130144","volume":"130","author":"CL Nobles","year":"2020","unstructured":"Nobles, C. L. et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J. Clin. Invest. 130, 673\u2013685 (2020).","journal-title":"J. Clin. Invest."},{"key":"3478_CR73","doi-asserted-by":"publisher","first-page":"e2116764119","DOI":"10.1073\/pnas.2116764119","volume":"119","author":"DR Principe","year":"2022","unstructured":"Principe, D. R. et al. XP-524 is a dual-BET\/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Proc. Natl Acad. Sci. USA 119, e2116764119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3478_CR74","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jcyt.2024.03.484","volume":"26","author":"GC Russell","year":"2024","unstructured":"Russell, G. C. et al. Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers. Cytotherapy 26, 842\u2013857 (2024).","journal-title":"Cytotherapy"},{"key":"3478_CR75","doi-asserted-by":"publisher","first-page":"2275457","DOI":"10.1080\/21645515.2023.2275457","volume":"19","author":"DT Peters","year":"2023","unstructured":"Peters, D. T., Savoldo, B. & Grover, N. S. Building safety into CAR-T therapy. Hum. Vaccin. Immunother. 19, 2275457 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"3478_CR76","doi-asserted-by":"publisher","first-page":"101186","DOI":"10.1016\/j.omtm.2024.101186","volume":"32","author":"JK Jadlowsky","year":"2024","unstructured":"Jadlowsky, J. K. et al. Long-term stability of clinical-grade lentiviral vectors for cell therapy. Mol. Ther. Methods Clin. Dev. 32, 101186 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3478_CR77","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3478_CR78","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ymthe.2020.11.007","volume":"29","author":"JM Jacobson","year":"2021","unstructured":"Jacobson, J. M. et al. Autologous CD4 T lymphocytes modified with a Tat-dependent, virus-specific endoribonuclease gene in HIV-infected individuals. Mol. Ther. 29, 626\u2013635 (2021).","journal-title":"Mol. Ther."},{"key":"3478_CR79","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1371\/journal.pcbi.0020157","volume":"2","author":"C Berry","year":"2006","unstructured":"Berry, C., Hannenhalli, S., Leipzig, J. & Bushman, F. D. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput. Biol. 2, e157 (2006).","journal-title":"PLoS Comput. Biol."},{"key":"3478_CR80","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/bioinformatics\/bts004","volume":"28","author":"CC Berry","year":"2012","unstructured":"Berry, C. C. et al. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 28, 755\u2013762 (2012).","journal-title":"Bioinformatics"},{"key":"3478_CR81","doi-asserted-by":"publisher","first-page":"E234","DOI":"10.1371\/journal.pbio.0020234","volume":"2","author":"RS Mitchell","year":"2004","unstructured":"Mitchell, R. S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234 (2004).","journal-title":"PLoS Biol."},{"key":"3478_CR82","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1101\/gr.6286907","volume":"17","author":"GP Wang","year":"2007","unstructured":"Wang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C. & Bushman, F. D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17, 1186\u20131194 (2007).","journal-title":"Genome Res."},{"key":"3478_CR83","doi-asserted-by":"crossref","unstructured":"Wang, G. P. et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 115, 4356\u20134366 (2010).","DOI":"10.1182\/blood-2009-12-257352"},{"key":"3478_CR84","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1093\/nar\/gkr140","volume":"39","author":"T Brady","year":"2011","unstructured":"Brady, T. et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res. 39, e72 (2011).","journal-title":"Nucleic Acids Res."},{"key":"3478_CR85","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/nm.2057","volume":"15","author":"R Gabriel","year":"2009","unstructured":"Gabriel, R. et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 15, 1431\u20131436 (2009).","journal-title":"Nat. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03478-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03478-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03478-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T18:02:08Z","timestamp":1744826528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03478-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3478"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03478-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.O.H.: consulting or advisory role with Blueprint Medicines and the American Board of Internal Medicine Subspecialty Board; research funding from Blueprint Medicines and Tmunity Therapeutics. J.J.M.: fees received from IASO Biotherapeutics, Poseida Therapeutics and Kite Pharma unrelated to this work; holds patents related to enhancing immune cell efficacy and predicting chimeric antigen responsiveness issued to Novartis. S.A.G.: support received and advisory capacities served for multiple entities within the pharmaceutical sector, including Novartis and Servier. N.V.F., D.L.P. and F.D.B.: engaged with Sana Biotechnology; N.V.F. also holds consultancy roles with Novartis and Syndax Pharmaceuticals and obtains funding from Kite Pharma. J.L.R.: grants received from Tmunity\/Kite outside the submitted work and is a co-founder of Tmunity Therapeutics and BlueWhale Bio with monetary compensation and equity. M.R.: patents related to CD19 CAR-T cells; consultant for NanoString, Bristol Myers Squibb, GlaxoSmithKline, Scaylite, Bayer and AbClon; research funding received from AbClon, NanoString, Oxford NanoImaging, viTToria Biotherapeutics, CURIOX and Beckman Coulter; scientific founder of viTToria Biotherapeutics. S.I.G.: stock ownership interests in Carisma Therapeutics; advisory role with Asher Bio; research funding from Carisma Therapeutics and Novartis; holds patents for chimeric antigen receptor T cells for acute myeloid leukemia. S.J.S.: consultant to various companies, including AstraZeneca, BeiGene, Celgene, Genentech, Genmab, Fate Therapeutics, Roche, Incyte, Juno Therapeutics, Legend Biotech, Loxo Oncology, MorphoSys, Mustang Biotech, Nordic Nanovector, Novartis and Regeneron; research funding received from AbbVie, Adaptive Biotechnologies, Celgene, DTRM, Genentech, Roche, Juno Therapeutics, Merck, Novartis, Incyte, Pharmacyclics and TG Therapeutics; honoraria from Celgene and Novartis; holds patents related to CD19 CAR-T cells and autologous co-stimulated T cells. A.D.C.: consulting with Janssen, GlaxoSmithKline, Bristol Myers Squibb\/Celgene, Genentech\/Roche, Pfizer, AbbVie, Arcellx and Ichnos. A.L.G.: consulting with Bristol Myers Squibb, Janssen, Novartis, GlaxoSmithKline, AbbVie, Regeneron, Gracell Bio and Legend; research funding from Novartis, Janssen, Tmunity and CRISPR Therapeutics; patents in CAR-T cell therapy with Novartis. P.D.S.: stock ownership interests in Johnson & Johnson, Novartis, Novo Nordisk, Pfizer, Merck and Amgen; consulting or advisory role with Tmunity Therapeutics. D.L.P.: membership on advisory boards for the National Marrow Donor Program, Kite\/Gilead, Janssen, Incyte, Sana Biotechnology and Verismo; equity holder in Genentech; honoraria from the American Society for Transplantation and Cellular Therapy; patents and royalties with Novartis, Tmunity and Wiley and Sons Publishing. S.L.M.: clinical trial support and advisory roles with Novartis and Wugen; pending patent with Novartis. B.L.L.: consultancy and advisory positions with Terumo, GlaxoSmithKline and Kite; co-founder and equity holder in Tmunity Therapeutics (acquired by Kite) and Capstan Therapeutics; membership on advisory boards for Avectas, Capstan Therapeutics (chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, Thermo Fisher Pharma Services and UTC Therapeutics; Alliance for Cancer Gene Therapy Board of Directors. D.L.S.: founder\u2019s equity and licensed intellectual property to Verismo Therapeutics, Vetigenics and Chimeric Therapeutics. A.C.: co-founder with equity in Tmunity Therapeutics. M.M.D.: intellectual property and patent rights concerning T-cell-based cancer immunotherapy, including royalty payments; research funding from Tmunity Therapeutics; member of the scientific advisory board for Cellares Corporation. F.H.: research funding from Danaher and Kite. E.A.S.: consultant for Janssen and Bristol Myers Squibb; grant funding from Sorrento and AbbVie. A.R.H.: consulting or advisory role with Olympus America and Novocure. N.B.H.: consulting or advisory role with Pfizer, Merck Sharp & Dohme, Calithera Biosciences, Eisai, Exelixis, AVEO and Roche\/Genentech; expert testimony with Eli Lilly. D.M.O.: inventor of intellectual property and received royalties related to targeted ErbB therapy in solid cancers and CAR-T cell therapy in solid tumors; inventor on multiple patents licensed by the University of Pennsylvania. J.S.: consulting or advisory role with Seattle Genetics, Bristol Myers Squibb, AstraZeneca, Pharmacyclics and Imbrium; research funding from Celgene, Seattle Genetics, Pharmacyclics, Merck, Bristol Myers Squibb, Incyte and AstraZeneca; research funding from Kite. R.A.: honoraria from Sigma-Tau; expert testimony with Wiggin and Dana. A.H.K.: honoraria from various organizations; consulting or advisory roles with ERYTECH Pharma, Imugene, SynCoreBio, Gritstone Bio, Roche\/Genentech, Ipsen, Five Prime Therapeutics, Tyme, Turning Point Therapeutics, Signatera and Syros Pharmaceuticals; speakers\u2019 bureau with Clinical Care Options; research funding from Celgene, Merck, Genentech\/Roche, Bristol Myers Squibb, AbGenomics International, Apexigen and Astellas Pharma. R.B.C.: consulting or advisory role with Heat Biologics, Takeda, Alkermes, Kyntherapeutics, Innate Pharma, Cantargia, Genocea Biosciences and AstraZeneca; research funding from Heat Biologics, Merck, Celldex, Innate Pharma, Kyntherapeutics, Xencor and Genocea Biosciences. C.H.J.: royalties paid from Novartis and Kite to the University of Pennsylvania; scientific co-founder and equity holder in Capstan Therapeutics, Dispatch Biotherapeutics and BlueWhale Bio; board membership with AC Immune; scientific advisory roles with various companies, including BlueSphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta and WIRB-Copernicus group. J.A.F.: patents and intellectual property in T cell-based cancer immunotherapy with royalties; funding from Tmunity Therapeutics and Danaher; consultancy with Retro Biosciences; scientific advisory board memberships with Cartography Bio, Shennon Biotechnologies, CellFe Biotech, OverT Bio and Tceleron Therapeutics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}